Fig. 3: PFS of real-world teclistamab in subgroups.

A PFS according to prior BCMA exposure. B PFS according to the type of prior BCMA-directed agent. C PFS according to cytogenetic risk. D PFS according to creatinine clearance. E PFS according to penta-drug refractoriness. F PFS according to MajesTEC-1 eligibility.